Tenaya Therapeutics (TNYA) Net Income towards Common Stockholders (2020 - 2026)

Tenaya Therapeutics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$19.3 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 28.26% year-over-year to -$19.3 million; the TTM figure through Mar 2026 stood at -$83.0 million (up 21.52% YoY), while the FY2025 annual figure was -$90.6 million, up 18.48% from the prior year.
• Net Income towards Common Stockholders was -$19.3 million for Q1 2026 at Tenaya Therapeutics, up from -$20.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$19.3 million in Q1 2026 to a low of -$33.5 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$27.6 million across 5 years, with a median of -$29.1 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders tumbled 137.1% in 2022, then gained 28.26% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$33.5 million in 2022, then gained by 10.68% to -$29.9 million in 2023, then grew by 20.37% to -$23.8 million in 2024, then climbed by 15.36% to -$20.2 million in 2025, then grew by 4.48% to -$19.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$19.3 million (Q1 2026), -$20.2 million (Q4 2025), and -$20.3 million (Q3 2025), per Business Quant data.